From Wikipedia, the free encyclopedia
Jump to: navigation, search
Systematic (IUPAC) name
1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Clinical data
Trade names Mefoxin
AHFS/Drugs.com monograph
MedlinePlus a682737
  • B
Legal status
Routes IV
Pharmacokinetic data
Metabolism minimal
Half-life 41-59 min
Excretion 85% urine
CAS number 35607-66-0 YesY
ATC code J01DC01
PubChem CID 441199
DrugBank DB01331
ChemSpider 389981 YesY
KEGG D02345 N
ChEBI CHEBI:209807 N
Chemical data
Formula C16H17N3O7S2 
Molecular mass 427.454 g/mol
 N (what is this?)  (verify)

Cefoxitin is a cephamycin antibiotic developed by Merck & Co., Inc., often grouped with the second−generation cephalosporins. It is sold under the brand name Mefoxin.


Cefoxitin acts by interfering with cell wall synthesis. Its activity spectrum includes a broad range of gram-negative and gram-positive bacteria including anaerobes. It is inactive in vitro to most strains of Pseudomonas aeruginosa and many strains of Enterobacter cloacae. Staphylococci resistant to methicillin/oxacillin should be considered resistant to cefoxitin. [1]

Cefoxitin is considered to be a strong beta-lactamase inducer, as are certain other antibiotics (such as imipenem).[2]

Spectrum of Bacterial Susceptibility[edit]

Cefoxitin has a broad spectrum of activity and has been used in the treatment of skin, bone, respiratory and urinary tract infections. Susceptible bacteria include some Staphylococci, Enterococci, Streptococci, and others. The following represents MIC susceptibility data for a few medically significant microorganisms.

  • Escherichia coli: 0.2 μg/ml - 64 μg/ml
  • Haemophilus influenzae: 0.5 μg/ml - 12.5 μg/ml
  • Streptococcus pneumoniae: 0.2 μg/ml - 1 μg/ml



  1. ^ Mefoxin Official FDA information at Drugs.com
  2. ^ Phillips I, Shannon K (1993). "Importance of beta-lactamase induction". Eur J Clin Microbiol Infect Dis. 12 Suppl 1: S19–26. PMID 8477758. 
  3. ^ http://www.toku-e.com/Assets/MIC/Cefoxitin.pdf